No Data
No Data
Sinolink: The results of the negotiations on drug prices in the United States have been announced, and the continuous procurement of medical devices domestically is ongoing.
Bullish on the development of the domestic medical devices industry in the second half of the year, with the industry's purchasing demand expected to accelerate recovery. At the same time, domestic leading companies in sub-sectors such as ultrasound and endoscopy, due to their strong competitiveness, are expected to further increase market share, with sales growth and profitability expected to return to an upward trend.
China NT Pharma Schedules Key Financial Results Meeting
NT Pharma (01011.HK) plans to hold a board of directors meeting on August 30 to approve mid-term performance.
NT Pharma (01011.HK) announced that the Board of Directors will hold a meeting on Friday, August 30, 2024 to approve the publication of the company's and its affiliates' mid-year performance through June 30, 2024.
NT PHARMA: DATE OF BOARD MEETING
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
CICC: The pharmaceutical sector has entered a value investment range, focusing on the domestic innovative drug industry chain and going overseas.
China International Capital Corporation released a research report stating that after three years of systematic adjustment, the pharmaceutical sector has entered the range of value investment.
No Data